{"task_id": "d6b75dbcd1d75326", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 284/464)", "text": "linical response in 3 4 days)\n274\nSeptic Arthritis\n\n--- Page 296 ---\nGout\nNEJM 2003 349:17\nCAUSES\nDECREASED URATE EXCRETION (90%)\n\u0002\nRENAL DISEASE\n\u0002\nDRUGS wCAN\u2019T LEAPw\nCyclosporine, Alcohol,\nNicotinic Acid, Thiazides, Loop diuretics, Etham\nbutol, ASA (low dose), Pyrazinamide\nINCREASED URATE PRODUCTION (10%)\n\u0002\nMETABOLIC SYNDROME\nobesity, hyperlipidemia,\nhypertension\n\u0002\nINCREASED METABOLISM\nalcohol, hemolytic ane\nmia, psoriasis, Lesch Nyhan syndrome\n\u0002\nNEOPLASTIC\nmyeloproliferative\ndisease,\nlym\nphoproliferative disease, chemotherapy\nPATHOPHYSIOLOGY\nIMBALANCE\ndecreased urate excretion and/or\nincreased urate production ! uric acid crystals\ndeposited in joints, skin, and kidneys ! arthritis,\ntophi, and renal failure. Gout almost never occurs in\npre menopausal women\nPRECIPITANTS\nsurgery,\ndehydration,\nfasting,\nbinge eating, binge drinking, exercise, trauma\nCLINICAL FEATURES\nSYMPTOMS\n\u0002\nARTHRITIS\nmono/oligo and asymmetric, espe\ncially first MTP joint. Podagra, inflammation\nof the first MTP joint, is the presenting symptom\nin 75% of gout patients. However, the first MTP\nis also commonly affected in pseudogout, psor\niatic arthritis, sarcoidosis, osteoarthritis, and\ntrauma\n\u0002\nTOPHI\nyellowish white nodular urate crystals col\nlection in subcutaneous tissues (particularly colder\nextremities such as ear, fingers, olecranon bursa,\nulnar aspect of forearm), bone, tendons (Achilles),\ncartilage, and joints. Generally painless but may\nlead to erosions\n\u0002\nKIDNEYS\nurolithiasis\n(radiolucent),\nuric\nacid\nnephropathy (reversible acute renal failure sec\nondary\nto\nacute\nlysis),\nurate\nnephropathy\n(chronic renal failure secondary to interstitial\ndeposits)\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, uric acid (sens 75%),\nAST, ALT, ALP, bilirubin, TSH, urinalysis, 24 h\nurine uric acid collection (<800 mg/day sug\ngests # excretion)\n\u0002\nIMAGING\njoint XR\nINVESTIGATIONS (CONT\u2019D)\n\u0002\nARTHROCENTESIS\nw3Cw (Cell count with diff,\nCulture and Gram stain, Crystal, for gout, sens\n85%, spc 100%)\nSPECIAL\n\u0002\nTOPHI ASPIRATION\nDIAGNOSTIC ISSUES\nSERUM URIC ACID LEVELS\nmay be falsely lowered\nin an acute attack\nJOINT X RAY\nsoft tissue swelling, normal joint\nspace, erosions (\u2018punched out\u2019\u2019 and sclerotic lesions\nwith overhanging edge)\nJOINT FLUID\nALWAYS confirm diagnosis with a\nsynovial fluid tap if possible. Microscopy shows pre\ndominantly neutrophilic infiltrate with some intracel\nlular monosodium urate crystals (needle shaped,\nnegative birefringence, i.e. yellow when parallel to\nplane of polarized light)\nMANAGEMENT\nACUTE\nNSAIDs (first line, avoid if renal/hepatic\nfailure; naproxen 375 500 mg PO BID \u00053 days, then\n250 375 mg PO BID \u00054 7 days; sulindac 150 200 mg\nPO BID \u00057 10 days; indomethacin 25 50 mg PO TID\n\u00053 days, then 100 mg PO div BID QID \u00054 7 days;\ncelecoxib 200 mg PO BID \u00051 day, then 100 mg PO BID\n\u00056 10 days). Systemic corticosteroids (avoid if\njoint sepsis not excluded; prednisone 30 60 mg PO\ndaily \u00053 days, then # 10 15 mg daily \u00053 days until\ndiscontinuation, triamcinolone 50 mg IM \u00051 dose).\nIntra articular corticosteroids (for mono and oli\ngoarthritis only. Methylprednisolone 100 150 mg\nintra articularly once). Colchicine 0.6 mg PO daily\nBID during acute attack (avoid the approach of giving\ncolchicine q1h until development of diarrhea)\nLONG TERM\nMANAGEMENT\npurine restricted\ndiet (# red meats, # seafood, \" low fat dairy products,\n\" fruit and veges). Allopurinol 50 300 mg PO daily\n(first line, xanthine oxidase inhibitor, renal correction\nrequired, do not give in acute attack; however,\ncontinue allopurinol if already on it prior to acute\nattack). Probenecid 250 1000 mg PO BID (first line,\n# renal urate reabsorption. Ensure normal renal func\ntion). Sulfinpyrazone 50 200 mg PO BID. Colchicine\n0.6 mg PO BID \u00056 months (for prophylaxis against\nrecurrent attacks only. Do not give colchicine IV)\nTREATMENT ISSUES\nLONG TERM THERAPY\nconsider if patients have\nfrequent attacks (\u00043/year, tophaceous deposits,\nGout\n275", "text_length": 3927, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 284/464)", "type": "chunk", "chunk_index": 283, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.636257", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.636970", "status": "complete", "chunks_added": 3}